RxDoctor Payments Data

Yulia Orlova, MD

Neurology · Jacksonville, FLNPI 1598000861

Payments from drug & device makers

$32,062in general payments, 2019–2025

Across 9 payments — averaging $3562.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$30K
  • AbbVie$1K
  • Lundbeck LLC$212
  • Angiodynamics, Inc.$18
$9,002in research payments, 2019–2025

Across 1 payment — averaging $9002.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

What the payments were for

  • Consulting fees$1,25079%
  • Food & beverage$32921%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly4$30,483
AbbVie(2 entities)2$1,349
Lundbeck LLC2$212
Angiodynamics, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,062 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$87,826
Medicare patients
111
Services billed
8,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate27$38,390
Emgality PenGalcanezumab-Gnlm43$32,524
Aimovig AutoinjectorErenumab-Aooe23$22,499
UbrelvyUbrogepant15$18,705
ReyvowLasmiditan Succinate14$15,718
QuliptaAtogepant11$14,782
Sumatriptan Succinate42$2,453
Gabapentin29$721
Carbamazepine ErCarbamazepine11$695
Nortriptyline Hcl20$570
RizatriptanRizatriptan Benzoate26$476
Topiramate17$248
Olanzapine14$234
Lidocaine Hcl ViscousLidocaine Hcl29$192
Cyclobenzaprine Hcl18$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,349$33,48726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →